Cargando…
Boldine Ameliorates Estrogen Deficiency-Induced Bone Loss via Inhibiting Bone Resorption
Osteoporosis is an enormous health problem caused by the imbalance between bone resorption and bone formation. The current therapeutic strategies for osteoporosis still have some limitations. Boldine, an alkaloid isolated from Peumus boldus, has been shown to have antioxidant and anti-inflammatory e...
Autores principales: | Chen, Kun, Lv, Zheng-tao, Cheng, Peng, Zhu, Wen-tao, Liang, Shuang, Yang, Qing, Parkman, Virginia-Jeni Akila, Zhou, Chen-he, Jing, Xing-zhi, Liu, Hui, Wang, Yu-ting, Lin, Hui, Liao, Hui, Chen, An-min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146032/ https://www.ncbi.nlm.nih.gov/pubmed/30271347 http://dx.doi.org/10.3389/fphar.2018.01046 |
Ejemplares similares
-
Cepharanthine Prevents Estrogen Deficiency-Induced Bone Loss by Inhibiting Bone Resorption
por: Zhou, Chen-he, et al.
Publicado: (2018) -
Micheliolide prevents estrogen deficiency-induced bone loss via inhibiting osteoclast bone resorption
por: Gan, Ziyang, et al.
Publicado: (2023) -
Sitagliptin, An Anti-diabetic Drug, Suppresses Estrogen Deficiency-Induced OsteoporosisIn Vivo and Inhibits RANKL-Induced Osteoclast Formation and Bone Resorption In Vitro
por: Wang, Chuandong, et al.
Publicado: (2017) -
TRPV6 is a potential regulator of bone resorption in bone loss induced by estrogen deficiency
por: Ma, Jun, et al.
Publicado: (2021) -
Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss
por: Qi, Dahu, et al.
Publicado: (2021)